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SHORT REPORT Open Access
The α7 nicotinic acetylcholine receptor
agonist, GTS-21, attenuates hyperoxia-
induced acute inflammatory lung injury by
alleviating the accumulation of HMGB1 in
the airways and the circulation
Ravikumar A. Sitapara1†, Alex G. Gauthier1†, Sergio I. Valdés-Ferrer2, Mosi Lin1 , Vivek Patel1, Mao Wang1,
Ashley T. Martino1, Jeanette C. Perron1, Charles R. Ashby Jr1, Kevin J. Tracey2, Valentin A. Pavlov2* and
Lin L. Mantell1,2*
Abstract
Background: Oxygen therapy, using supraphysiological concentrations of oxygen (hyperoxia), is routinely
administered to patients who require respiratory support including mechanical ventilation (MV). However, prolonged
exposure to hyperoxia results in acute lung injury (ALI) and accumulation of high mobility group box 1 (HMGB1) in the
airways. We previously showed that airway HMGB1 mediates hyperoxia-induced lung injury in a mouse model of ALI.
Cholinergic signaling through the α7 nicotinic acetylcholine receptor (α7nAChR) attenuates several inflammatory
conditions. The aim of this study was to determine whether 3–(2,4 dimethoxy-benzylidene)-anabaseine
dihydrochloride, GTS-21, an α7nAChR partial agonist, inhibits hyperoxia-induced HMGB1 accumulation in the airways
and circulation, and consequently attenuates inflammatory lung injury.
Methods: Mice were exposed to hyperoxia (≥99% O2) for 3 days and treated concurrently with GTS-21 (0.04, 0.4 and
4mg/kg, i.p.) or the control vehicle, saline.
Results: The systemic administration of GTS-21 (4 mg/kg) significantly decreased levels of HMGB1 in the airways and
the serum. Moreover, GTS-21 (4 mg/kg) significantly reduced hyperoxia-induced acute inflammatory lung injury, as
indicated by the decreased total protein content in the airways, reduced infiltration of inflammatory monocytes/
macrophages and neutrophils into the lung tissue and airways, and improved lung injury histopathology.
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Conclusions: Our results indicate that GTS-21 can attenuate hyperoxia-induced ALI by inhibiting extracellular HMGB1-
mediated inflammatory responses. This suggests that the α7nAChR represents a potential pharmacological target for
the treatment regimen of oxidative inflammatory lung injury in patients receiving oxygen therapy.
Keywords: Hyperoxia, Lung injury, a7nAChR, Vagus nerve, Cholinergic anti-inflammatory pathway, Inflammatory reflex,
Sterile inflammation
Introduction
Patients with hypoxemia and acute respiratory failure
frequently require the administration of hyperoxia (in-
spired content of O2 > 21%) (Carvalho 1998; Snider and
Rinaldo 1980; Han and Mallampalli 2015). In this con-
text, hyperoxia can become a lifesaving intervention in
clinical scenarios as diverse as preterm newborns, adults
with respiratory distress, or patients suffering from
severe acute respiratory decline, such as patients with
COVID-19 (Windhorst et al. 2009; Silversides and
Ferguson 2013; Giwa et al. 2020; Guan et al. 2020;
Huang et al. 2020). However, prolonged exposure to
hyperoxia is associated with oxygen toxicity, due to the
excessive production of reactive oxygen species (ROS),
which can lead to oxidative stress-mediated acute
inflammatory lung injury, known as hyperoxia-induced
acute lung injury (HALI) (Kallet and Matthay 2013;
Morrow et al. 2007; Matthay and Zimmerman 2005).
This oxidative stress-mediated HALI is characterized
by 1) an influx of inflammatory cells, including poly-
morphonuclear neutrophils (PMNs); 2) enhanced cyto-
kine production; 3) injury and death of pulmonary
epithelial and endothelial cells; 4) pulmonary protein-
aceous edema; 5) destruction of the alveolar-capillary
barrier; and 6) impaired gas exchange, leading to the se-
vere morbidity and mortality in patients on ventilation
(Bhandari and Elias 2006; Crapo 1986; Slutsky 1999; van
Zoelen et al. 2008). In this context, pro-inflammatory
chemokines and cytokines have been implicated in neu-
trophil recruitment into the lungs (Jiang et al. 2017;
Matthay et al. 2012; Belperio et al. 2002; Olson and Ley
2002). However, the specific molecular mechanisms
underlying cytokine-mediated HALI remain to be eluci-
dated. Clinically, there are no efficacious treatments that
significantly reduce the inflammatory lung injury in
patients receiving oxygen therapy.
Previously, we have shown that prolonged exposure to
hyperoxia induces the accumulation of high mobility
group box-1 protein (HMGB1) in mouse airways
(Entezari et al. 2014). The mechanistic role of HMGB1
in oxidative stress-induced ALI is incompletely under-
stood; extracellular HMGB1, either actively secreted by
immune cells or passively released by necrotic cells, has
been implicated in the pathophysiology of a variety of
inflammatory conditions (Scaffidi et al. 2002; Yang et al.
2001), such as sepsis and rheumatoid arthritis
(Andersson et al. 2000; Taniguchi et al. 2003; Wang
et al. 1999; Wang et al. 2004). The inactivation of
HMGB1 with specific anti-HMGB1 antibodies increased
the survival of animals with severe polymicrobial sepsis,
reduced high tidal volume ventilation-induced lung
injury, and diminished endotoxin and hemorrhage-
induced increases in pulmonary levels of inflammatory
cytokines (Abraham et al. 2000; Lutz and Stetkiewicz
2004; Ogawa et al. 2006; Ueno et al. 2004). In addition,
an increase in the levels of HMGB1 in the plasma and
lung epithelial-lining fluids has been reported in patients
with ALI (Kolliputi et al. 2010; Misharin et al. 2013).
Extracellular HMGB1, a potent pro-inflammatory medi-
ator (Wang et al. 1999), can initiate an inflammatory
response, facilitating the progression of sepsis and ALI
(Entezari et al. 2014; Abraham et al. 2000; Kolliputi et al.
2010; Crapo et al. 1982; Liu et al. 2008). Currently, the
role of HMGB1 in oxidative stress-induced ALI remains
to be elucidated. We have previously shown a significant
correlation between airway HMGB1 levels and oxidative
lung injury induced by hyperoxia (Entezari et al. 2014).
The exposure of mice to hyperoxia (≥99% O2) results in
an increased accumulation of HMGB1 in the mouse air-
ways and the administration of anti-HMGB1 antibodies
significantly reduced the severity of HALI (Entezari et al.
2014). These results indicate that the high levels of air-
way HMGB1 play a critical role in lung injury induced
by oxidative stress under hyperoxic conditions. There-
fore, targeting the accumulation of airway HMGB1 may
be of benefit in the treatments of patients with HALI.
The activation of α7 nicotinic acetylcholine receptors
(α7nAChRs) plays a critical role in mediating the vagus
nerve-based inflammatory reflex and specifically its efferent
arm, termed the cholinergic anti-inflammatory pathway
(Wang et al. 2003; Borovikova et al. 2000). Its activation re-
sults in decreased translocation of HMGB1 from the nucleus
to the cytoplasm, with subsequent release into the extracellu-
lar milieu (Wang et al. 2003; Brewer et al. 1996; Bustin 2001;
de Jonge and Ulloa 2007; Pavlov et al. 2007). Lung cells ex-
press high levels of α7nAChR, which could be targeted to re-
duce the accumulation of extracellular HMGB1 (Bustin
2001; Pavlov et al. 2007; Calogero et al. 1999). GTS-21, a par-
tial agonist of α7nAChR (Chastre and Fagon 2002; Cook
et al. 1998), has been previously used therapeutically for
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experimental sepsis and in other preclinical conditions (Pav-
lov et al. 2007; Kang et al. 2014; Tarnawski et al. 2018; Mav-
ropoulos et al. 2017). GTS-21 has been used in human
studies and has a favorable safety profile at doses up to 450
mg/day (Kitagawa et al. 2003; Kox et al. 2011). The aims of
this study were to determine the effects of GTS-21 on (a) the
accumulation of extracellular HMGB1 in the animals sub-
jected to prolonged exposure to hyperoxia, (b) attenuating
hyperoxia-induced lung injury and (c) hyperoxia-induced
pulmonary pro-inflammatory responses, especially the infil-




GTS-21 was obtained from Abcam (Cambridge, MA,
USA). The pH of the GTS-21 solution was adjusted to 7
before intra-peritoneal injection in mice. 0.9% normal
saline solution was used as the control vehicle.
Animal studies
C57BL/6 mice (male, 8 to 12 weeks old; The Jackson La-
boratory, Bar Harbor, ME, USA) were used in this study,
in accordance with the Institutional Animal Care and
Use Committees of St. John’s University. The mice were
housed in a specific pathogen-free environment main-
tained at 22 °C in ≈50% relative humidity with a 12-h
light/dark cycle. All mice had ad libitum access to stand-
ard rodent food and water. Mice were exposed to hyper-
oxia as previously described (Patel et al. 2013). Briefly,
animals were placed in micro isolator cages (Allentown
Caging Equipment, Allentown, NJ, USA) that were kept
in a Plexiglas chamber (BioSpherix, Lacona, NY, USA)
and exposed to ≥99% O2 or remained in room air for 72
h. Mice exposed to hyperoxia were randomized to re-
ceive either intraperitoneally administered GTS-21 (0.04,
0.4 and 4mg/kg) or the control vehicle, saline, every 8 h,
starting 32 h after the onset of hyperoxic exposure. At
the end of hyperoxic exposure, mice were euthanized
with intraperitoneal sodium pentobarbital (120 mg/kg)
to obtain bronchoalveolar lavage (BAL) fluid samples or
lung tissues, as described below, for further analysis.
Bronchoalveolar lavage fluids and serum collection
Murine BAL fluid containing proteinaceous debris and
cells was obtained as previously described (Patel et al.
2013; Sitapara et al. 2014). Briefly, mice were euthanized
by an intraperitoneal injection of sodium pentobarbital
(120 mg/kg). Following a 1- to 2-cm incision made on
the neck, the trachea was dissected and a 20-gauge ×
1.25-in. intravenous catheter was inserted caudally into
the lumen of the exposed trachea. The lungs were gently
lavaged twice with 1 mL of a sterile, nonpyrogenic
phosphate-buffered saline (PBS) solution (Mediatech,
Herndon, VA, USA). The BAL samples were centrifuged
at 4 °C at 3200 x g and the resultant supernatants were
stored at − 80 °C and pellets used for cell content ana-
lysis. For serum collection, whole blood was collected by
cardiac puncture and allowed to coagulate for 30 min at
room temperature. Next, samples were centrifuged at
2000 x g for 10 min at 4 °C and the resulting supernatant
was stored as serum samples. Proteins in normalized
volumes of BAL and serum samples were separated by
SDS-PAGE and HMGB1 concentrations were deter-
mined by Western blot analysis as described below.
Total BAL protein content was analyzed by bicinchoni-
nic acid (BCA) assay in BAL samples. For cell content
analysis in BAL samples, cell pellets were subjected to
red blood cell lysis. Next, differential cell analysis was
performed by depositing a monolayer of cells onto a
cover slip using a Shandon Cytospin 2 centrifuge (Mar-
shall Scientific, Hampton, NH) and then stained with
Hema 3 solution kit (Fisher Scientific, Hampton, NH)
per the manufacturer’s instructions or by flow cytometry
analysis as described below.
Measurement of HMGB1
The concentrations of HMGB1 in BAL samples were deter-
mined using immunoblotting analysis with an anti-
HMGB1 antibody, as previously described (Wang et al.
1999). In brief, samples were separated first on SDS-PAGE.
Next, the proteins were electrotransferred to a polyvinyle-
dene difluoride membrane, and blocked with 5% nonfat dry
milk in Tris-buffered saline with 0.1% Tween-20 (TBST).
The membrane was incubated with anti-HMGB1 (1:1000),
washed with TBST, followed by incubation with a goat
anti-rabbit horseradish peroxidase-coupled secondary anti-
body (1:10,000) (BioRad, Hercules, CA). After washing,
antibody binding was detected using Enhanced Chemilu-
minescence Plus Western blotting detection reagents
(Amersham Pharmacia Biotech, Piscataway, NJ). Western
blots were scanned with a UVP Biospectrum 600 Imaging
System (Vision Works LS, Upland, CA), and the band
intensities were quantified using Image J analysis software
version 2.0.0 (Works LS, Upland, CA).
Histopathology
Histopathological evaluation was conducted in paraffin-
embedded tissues as previously described (Entezari et al.
2014). Prior to removal from the animal, the lungs were
instilled with buffered formalin solution through a 20-
gauge angiocatheter placed in the trachea. The lungs
were then immersed in buffered formalin overnight and
processed for conventional paraffin histology. The
sections were stained with hematoxylin and eosin and
examined with an Evos XL core microscope (Life Tech-
nologies, Grand Island, NY). Lung injury scores were
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performed by three blinded independent investigators
using the scoring criteria described in Szarka et al. 1997.
Immunohistochemistry
Macrophage/monocyte staining was performed on cryo-
sectioned lung tissue as previously described (Martino
et al. 2011). Briefly, before removal from the animal, the
lungs were rinsed with PBS and then instilled with 30%
sucrose solution through a 20-gauge angiocatheter
placed in the trachea. The lungs were frozen in an opti-
mal cutting temperature (OCT) solution. The sections
from lung tissue blocks cryopreserved in OCT were
mounted on Superfrost plus slides. The sections were
fixed for 10 min at room temperature (RT) in acetone
and then air-dried for 15 min. An HRP immunohisto-
chemistry staining protocol for CD11b was used with
hematoxylin counter stain and mounted with Vecta-
mount AQ aqueous mounting media (Vector Labs,
Burlingame, CA). In brief, the sections were blocked (5%
goat serum in PBS) for 30 min at RT, followed by PBS
rinse. Biotinylated CD11b primary antibody (Thermo
Scientific, Waltham, MA) was added at a 1:100 dilution
in PBS with 1% goat serum for 60min at RT, or with
anti-HMGB1 antibody (Cell Signaling Technologies,
Danvers, MA), at a 1:100 dilution overnight at 4 °C,
followed by a PBS rinse. Peroxidase was blocked for 10
min at RT with peroxide suppressor (Thermo Scientific).
After the PBS rinse, streptavidin-HRP (BD Biosciences,
San Jose, CA) was added at a 1:100 diluted in PBS with
1% goat serum for 30min at RT in the dark. Next, slides
were stained with a 3,3- diaminobenzidine (DAB) buffer
kit and hematoxylin stain (Vector Labs) per the manu-
facturer’s protocol. At least 15 images per slide were
captured at 200x magnification using an inverted light
microscope. CD11b positive cells were counted manually
from captured images. Data were calculated per square
centimeter.
Flow Cytometric analysis
BAL cells were incubated for 10 min at 4 °C with an
anti-mouse CD16/32 antibody (1:200; Biolegend, San
Diego, CA) to block non-specific binding, followed by
incubation with a FITC-conjugated anti-mouse CD11b
(1:200; Biolegend, San Diego, CA) and an AF 700-
conjugated anti-mouse CD11c (1:200, Biolegend) anti-
bodies for 30 min at 4 °C. Data were collected on a
BD LSR Fortessa flow cytometer using FACSDiva
software (Becton Dickinson, Mountain View, CA) and
analyzed using FlowJo software (Tree Star, San Carlos,
CA). A range of 20,000–50,000 cells was analyzed per
sample. The initial gating eliminated debris and red
blood cells. Next, consecutive gates, were set to
identify CD11c+ and CD11b+ cells, as previously de-
scribed (Swirski et al. 2009; Valdés-Ferrer et al. 2013).
The relative expression of CD11c was used to distin-
guish CD11c-positive alveolar macrophages (CD11c+,
CD11b+) and CD11c-negative infiltrated cells
(CD11cneg, CD11b+). Fluorescence minus one (FMO)
controls were used for proper gating.
Statistical analysis
All the data was analyzed using GraphPad Prism statis-
tical software. The results are presented as the mean ±
SEM. The data were analyzed for statistical significance
according to unpaired t-test, and analysis of variance
(ANOVA) with Dunnett’s post hoc analysis. The survival
data were analyzed using the Kaplan-Meier analysis. The
a priori p value was p < 0.05.
Results and discussion
Prolonged exposure to hyperoxia induces the accumula-
tion of HMGB1 in the airways of the exposed subjects,
which can be a critical contributor to HALI (Entezari
et al. 2014; Abraham et al. 2000; Ueno et al. 2004; Wang
et al. 2019). Similar to other types of acute lung injury,
HALI is characterized by the injury/damage of alveolar
epithelial cells and pulmonary endothelial cells. The
resulting impairment of the alveolar barrier can be
assessed by measuring the protein content released into
the airways and the presence of elevated leukocyte
counts (Doerschuk 2000; Barnett and Ware 2011; Mokra
and Kosutova 2015; Pittet et al. 1997). As shown in
Fig. 1a, hyperoxia-induced inflammatory lung injury was
characterized by increased protein leakage into the air-
ways (Entezari et al. 2014), and 4 mg/kg i.p. of GTS-21
partially rescued mice from hyperoxia-induced pulmon-
ary accumulation of proteins in the airways (1687 μg ±
242 μg of protein/mL, versus 99% O2 control vehicle
2618 ± 298 μg of protein/mL, p < 0.05). Similarly, 4 mg/
kg i.p. of GTS-21 significantly attenuated hyperoxia-
induced inflammatory lung injury (Fig. 1b and c). As we
have previously reported, there is a significant positive
correlation between the hyperoxia-induced inflammatory
lung injury, including the infiltration of neutrophils, and
the severity of HALI in mice exposed to hyperoxia
(Entezari et al. 2014). This damage is also observed in
mice exposed to hyperoxia and subjected to control ve-
hicle treatment, as compared to mice that remained in
room air (Fig. 1b and c, 1.88 ± 0.29 versus 0.352 ± 0.07 of
the room air control, p < 0.05). Hyperoxia-induced acute
inflammatory lung injury was attenuated by the adminis-
tration of 4 mg/kg i.p. of GTS-21 (Fig. 1b and c, 1.26 ±
0.16 score versus control vehicle 1.88 ± 0.29 score, p <
0.05). Hyperoxia induces excessive production of ROS,
causing oxidative stress-mediated ALI (Bhandari and
Elias 2006; Zhang et al. 2003). The increased infiltration
of ROS-releasing neutrophils can result in further oxida-
tive stress-induced cell damage and lung injury (Steer
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et al. 2013; Han et al. 2018). Oxidative stress has also
been implicated in LPS-induced ALI, which produces an
increase in neutrophil recruitment to the lung, pul-
monary cell apoptosis and an increase in the airway
levels of HMGB1, TNFα and polymorphonuclear cells
(Xie et al. 2012).
Extracellular HMGB1, either actively secreted by im-
mune cells or passively released by necrotic cells, has
been implicated in the pathophysiology of a variety of in-
flammatory diseases (Scaffidi et al. 2002; Yang et al.
2001; Bonaldi et al. 2003). Airway HMGB1 induces sig-
nificant pro-inflammatory responses in the lungs of mice
exposed to hyperoxia (Entezari et al. 2014). The inactiva-
tion of HMGB1 with specific, neutralizing anti-HMGB1
antibodies significantly decreases inflammatory lung in-
jury and increases the survival of animals in several
mouse models of ALI (Entezari et al. 2014; Abraham
et al. 2000; Wang et al. 2019). The inactivation of
HMGB1 with a neutralizing antibody or the activation of
α7nAChR with acetylcholine or GTS-21 inhibits the re-
ceptor for advanced glycation end products (RAGE)-
mediated endocytosis of extracellular HMGB1 and
HMGB1-LPS complexes, resulting in in a decrease in
TNFα secretion and cell death in macrophages (Yang
et al. 2019). ALI (induced by either polymicrobial sepsis,
high tidal volume ventilation, endotoxin, or hemorrhage)
is attenuated by the administration of anti-HMGB1
antibodies, which may be a result of decreased pro-
inflammatory responses (Abraham et al. 2000; Lutz and
Stetkiewicz 2004; Ogawa et al. 2006; Ueno et al. 2004).
Accordingly, this study evaluated the levels of extracellu-
lar HMGB1 in both BAL (Fig. 2a) and serum samples
(Fig. 2b), obtained from animals exposed to either hyper-
oxia or remained in room air. Similar to previous obser-
vations (Entezari et al. 2014), mice exposed to hyperoxia
have significant levels of airway HMGB1 (Fig. 2a)
(Entezari et al. 2014). The administration of 4 mg/kg i.p.
of GTS-21 significantly reduced HMGB1 concentration
in the airways (Fig. 2a) (9.38 ± 1.57 A.U. versus control
vehicle 15.24 ± 1.8 A.U., p < 0.05). Next, we determined
whether HMGB1 perturbation in the lung appears only
in the airways. As shown in Fig. 2b, no detectable
Fig. 1 Systemic administration of GTS-21 decreases lung injury in mice exposed to prolonged hyperoxia. C57BL/6 mice were exposed to either ≥99% O2 for 3
days or 21% O2 (room air). Mice were randomized to receive either GTS-21 (0.04, 0.4 and 4mg/kg) or saline, administrated by intraperitoneal injection every 8 h
starting at 32 h following the onset of hyperoxic exposure. Lungs and BAL were harvested at the end of hyperoxia treatment. a The total protein content in the
BAL was measured as a marker of lung injury. b-c Lungs, harvested at the end of hyperoxic exposure, were fixed, embedded and sectioned. Images of the
Hematoxylin-eosin-stain of the lung sections from room air samples (RA), and hyperoxic samples from mice treated with either vehicle saline control (0m/kg)
or GTS-21, (4mg/kg) are shown (b) and their lung histopathological scores assessed (c). Data represent the mean± SEM from three independent experiments
(n=6–10 mice/group). *p<0.05, compared with mice receiving normal saline
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HMGB1 was observed in the circulation, reflecting our
previous findings (Entezari et al. 2014). While exposure
to hyperoxia for 3 days caused a markedly accumulation
of extracellular HMGB1 in the serum, GTS-21 (4 mg/kg)
significantly attenuated this accumulation (0.6 × 104 ±
0.02 × 104 A.U. versus control vehicle 1.2 × 104 ± 0.4 ×
104 A.U. p < 0.05). Moreover, immunohistochemical ana-
lysis indicated (Fig. 2c) that hyperoxia-induced HMGB1
nuclear-to-cytoplasmic translocation in lung structural
cells, as previously reported (Entezari et al. 2014), a
critical step required for HMGB1 secretion, was signifi-
cantly suppressed in GTS-21 (4 mg/kg i.p.) treated mice.
We and others have shown that GTS-21 1) inhibits
HMGB1 release from immune cells that were stimulated
by hyperoxia (Sitapara et al. 2014) or LPS and 2) de-
creases levels of serum HMGB1 in a mouse model of
endotoxemia (Pavlov et al. 2007; Rosas-Ballina et al.
2009). Taken together, these data suggest that GTS-21
attenuates HALI by significantly reducing the accumula-
tion of extracellular HMGB1, attenuating its inflamma-
tory effects both systematically and in the lung and
subsequently ALI in hyperoxia-exposed subjects.
Interestingly, the increase in the levels of extracellular
HMGB1 in the airways and serum (Fig. 2) occurred con-
comitantly with a significant increase in the infiltration
of leukocytes into the airways in mice subjected to
Fig. 2 GTS-21 inhibits hyperoxia-induced translocation and accumulation of HMGB1 in the mouse airways and circulation. C57BL/6 mice were
exposed to either 21% O2 (room air) or to ≥99% O2 and treated with vehicle (0mg/kg) or GTS-21 (4mg/kg), as described in Fig. 1. Bronchoalveolar
lavage, whole blood, and lungs were harvested at the end of hyperoxia exposure. a A representative image of Western blots showing immunoreactive
bands of HMGB1 in the mouse BAL samples. The bar graph shows the integrated density value of the HMGB1 bands of the BAL of hyperoxic mice,
administered with normal saline or GTS-21 (n = 10 mice/group). b A representative Western blot for HMGB1 in mouse serum and the integrated density
values for each group (N.D., not detected) (n = 3 mice/group). c Representative immunohistochemical staining for HMGB1 in mouse lungs (arrows
indicate HMGB1 in nucleus, asterisks represent HMGB1 present in cytoplasm) (n = 3 mice/group). *p < 0.05, compared with mice receiving normal saline
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Fig. 3 (See legend on next page.)
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prolonged exposure to hyperoxia (Fig. 3a). Similar to
other inflammatory diseases, leukocyte infiltration plays
a pivotal role in facilitating hyperoxia-induced inflamma-
tory lung injury (Kang et al. 2014; Wang et al. 2019;
Grommes and Soehnlein 2011). Although GTS-21 did
not significantly reduce the infiltration of leukocytes into
the airways, a small number of leukocytes were present
in the airways of mice treated with 4 mg/kg i.p. of GTS-
21 (Fig. 3a). The increased levels of airway HMGB1 have
been reported to exacerbate ALI due to neutrophilic in-
flammation (Andersson and Tracey 2011). Extracellular
HMGB1 produces inflammation due to its interaction
with certain chemokine and cytokine receptors (Entezari
et al. 2014; Wang et al. 1999; Abraham et al. 2000; Ente-
zari et al. 2012). We and others have reported that the
intra-tracheal administration of HMGB1 induces a sig-
nificant inflammatory response characterized by the in-
filtration of neutrophils into the lungs of mice (Entezari
et al. 2014; Abraham et al. 2000). In addition, in a mouse
model of HALI, we have shown that HMGB1 accumu-
lates in the airways prior to infiltration of neutrophils
into the airways and the onset of lung injury (Entezari
et al. 2014). In the present study, the attenuated extra-
cellular HMGB1 accumulation in the airways and serum
of mice treated with 4 mg/kg i.p. of GTS-21 was not ac-
companied by a significant reduction in total leukocyte
(See figure on previous page.)
Fig. 3 Systemic administration of GTS-21 inhibits infiltration of neutrophils and monocytes into the airways of mice exposed to hyperoxia. C57BL/
6 mice were exposed to room air (21% O2) or hyperoxia (≥99% O2) and treated with vehicle (0 mg/kg) or GTS-21 (4 mg/kg), as described in Fig. 1.
a The total amount of leukocytes in the BAL were determined by hemocytometer. b Cells from the BAL samples were analyzed using differential
cell staining. Arrows show the presence of neutrophils stained with eosin and methylene blue in BAL samples. c The total number of infiltrated
neutrophils in the BAL samples. d-f Cells from BAL were labeled with anti-CD11b and anti-CD11c antibodies and analyzed by flow cytometry
(d-e); MCP-1 were analyzed by ELISA (f). d Representative gating for CD11b+hi and CD11clow cells in the BAL. e The graph is a representative of
two independent experiments. f The bar graph for MCP-1 expression in BAL. Data is represented as the mean ± SEM (n = 2–6 per group).
*p < 0.05, compared with mice receiving normal saline
Fig. 4 The sytemic administration of GTS-21 inhibits the infiltration of CD11b+ monocytes/macrophages in the lungs of mice exposed to hyperoxia.
C57BL/6 mice were exposed to ≥99% O2 and treated with vehicle (0mg/kg) or GTS-21 (4mg/kg) as described in Fig. 1. The lungs were perfused with
sucrose, frozen in OCT and cryosectioned. Immunohistochemistry was performed to detect CD11b. a Representative images of lung sections showing
DAB positive cells from either control or GTS-21-treated mice. b The total number of CD11b positive DAB stain per field. BAL was harvested at the end
of hyperoxia exposure. c-d Cells from the BAL and blood samples were labeled with CD11b and Ly6c antibodies and analyzed by flow cytometry.
c Gating for CD11b+ and Ly6c cells in the BAL is shown. d The quantification of the total number of CD11b+ and Ly6c+ in BAL and blood samples
analyzed by flow cytometry. Data represent the mean ± SEM from two independent experiments (n = 4 mice/group)
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counts in the airways (Fig. 3a). However, there was a sig-
nificant dose-dependent decrease in the infiltration of
neutrophils (Fig. 3b and c). Furthermore, the administra-
tion of 4 mg/kg i.p. of GTS-21 significantly decreased the
infiltration of CD11clow CD11bhi monocytes into the air-
ways (1.71 ± 0.52 × 104 versus control vehicle 16.19 ±
5.36 × 104/ml, p < 0.05, Fig. 3d and e). Congruent with
this finding, the levels of monocyte chemotactic protein-
1 (MCP-1), a proinflammatory cytokine involved in the
recruitment of monocytes (Lim et al. 2015), were signifi-
cantly increased in the airways of hyperoxic animals and
this increase was significantly attenuated in mice treated
with 4mg/kg i.p. of GTS-21 (p < 0.05, Fig. 3f). Thus,
these data suggest that the administration of GTS-21 at-
tenuates HALI by decreasing the accumulation of airway
HMGB1 and MCP-1, leading to a decrease in the infil-
tration of neutrophils and monocytes in the airways.
These results are consistent with previous reports show-
ing that α7nAChR agonists such as nicotine, PNU-
282987 and DMAB-inhibit leukocyte infiltration in the
lungs in mouse models of endotoxemia and E. coli
pneumonia (Pavlov et al. 2007; Su et al. 2010).
The results shown in Fig. 1b and c indicate that pro-
longed exposure to hyperoxia can significantly increase
the lung injury score, which includes increased cellulari-
zation. To determine whether the increased lung injury
score in hyperoxic mice results from an increase in the
infiltration of macrophages into the lung tissue, lung
tissues were immunolabelled for CD11b, a pan-
macrophage marker for both residential macrophages/
monocytes and those recruited (Misharin et al. 2013; Yu
et al. 2016; Bronte et al. 2016). The results (Figs. 4a and
b) indicated that hyperoxia significantly increased the
macrophages/monocytes in lung tissues (Fig. 4a and b).
Furthermore, GTS-21 significantly decreased the
hyperoxia-induced CD11b+ macrophage/monocyte infil-
tration in lung tissue (21.9 ± 3.0 cells/field versus control
vehicle 10.8 ± 1.5 cells/field, p < 0.05; Fig. 4a and b).
Decreasing the infiltration of circulating pro-
inflammatory monocytes into the lung has been shown
to play an important role in attenuating inflammatory
lung diseases (Jiang et al. 2017; Wang et al. 2019; Zhang
et al. 2018). It has been suggested that the increased ex-
pression of the Ly6C surface antigen can be used to de-
fine the inflammatory status of monocytes in the
circulation and after tissue infiltration (Kratofil et al.
2017). To further assess whether the macrophages/
monocytes in hyperoxic mice are pro-inflammatory, the
expression of Ly6C was determined in macrophages/
monocytes isolated from mouse serum and lung lavage
fluids. Flow cytometric analysis of macrophages/mono-
cytes in serum and BAL fluids from hyperoxia-exposed
mice treated with 4 mg/kg i.p. of GTS-21 indicated a sig-
nificant reduction in the accumulation of CD11b+ and
Fig. 5 Suggested pathways of GTS-21-mediated attenuation of HALI. In cells, including lung cells, HMGB1 shuttles between the nucleus and
cytoplasm. Under room air, the rate of HMGB1 nuclear import exceeds that of re-diffusion plus export. Thus, HMGB1 appears predominantly or
solely in the nucleus. The prolonged exposure to hyperoxia induces HMGB1 translocation from the nucleus to the cytoplasm. The α7nAChR
agonist, GTS-21, inhibits hyperoxia-induced translocation and subsequent release of nuclear HMGB1, and its accumulation in the airways and the
circulation. As a result, GTS-21 is efficacious in attenuating hyperoxia-induced infiltration of leukocytes, including neutrophils and inflammatory
monocytes, into the airways, thereby significantly reducing hyperoxia-induced inflammatory lung injury
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Ly6C+ hi pro-inflammatory monocytes in the blood
(3.68 ± 0.52 × 104 versus control vehicle 6.33 ± 1.05 ×
104/ml, p < 0.05, Fig. 4c). However, the reduction of
airway inflammatory macrophages/monocytes was not
significant (0.691 ± 0.243 × 104 versus control vehicle
0.891 ± 0.173 × 104/ml, Fig. 4d).
The activation of α7nAChR can also inhibit endothe-
lial cell activation, thus affecting leukocyte recruitment
in acute inflammation (Saeed et al. 2005). It has been
reported that the local activation of α7nAChR in the
lungs by the intra-tracheal administration of either nico-
tine (a non-selective agonist) or PNU-282987 (a selective
α7nAChR agonist) significantly attenuates the acid-
induced increase in lung permeability and edema, and
the protective effect of nicotine is abolished by methylly-
caconitine (MLA), an antagonist of α7nAChR (Su et al.
2007). It should be noted that the protective effects of
GTS-21 treatment may be due, in part, to its effect on
non-α7nAChR cellular targets that produce anti-
inflammatory efficacy. For example, in LPS-stimulated
primary α7nAChR knockout macrophages, GTS-21 sup-
pressed TNFα and IL-6 secretion (Garg and Loring
2019). Regardless of whether GTS-21 is functioning
through α7nAChR or other receptor-mediated pathways,
the results presented in this study reveal that GTS-21
has protective efficacy for HALI by attenuating several
markers of inflammation (Fig. 5). Thus, this study
indicates that GTS-21, an α7nAChR partial agonist, can
significantly attenuate HALI by modulating the inflam-
matory response induced by hyperoxia.
Conclusions
To our knowledge, this study is the first to report that the
systemic administration of GTS-21 decreases hyperoxia-
induced acute inflammatory lung injury. The development of
HALI is due, in part, to the accumulation of extracellular
HMGB1 in the airways and the circulation. GTS-21 signifi-
cantly decreases the hyperoxia-induced release of HMGB1
from hyperoxia-compromised lung cells into the airways and
the circulation. This, in turn, can effectively attenuate
hyperoxia-induced infiltration of inflammatory neutrophils
and monocytes. Therefore, targeting pathways that block the
accumulation of extracellular HMGB1 by GTS-21 may pro-
vide a novel approach for developing therapies to treat oxida-
tive stress-induced inflammatory lung injury in patients on
oxygen therapy. Moreover, these findings are especially per-
tinent in light of the requirement for prolonged ventilation
in severe cases of COVID-19.
Abbreviations
α7nAChR: Alpha 7 nicotinic acetylcholine receptor; BAL: Bronchoalveolar
lavage; GTS-21: [3-(2,4 dimethoxy- benzylidene)-anabaseine dihydrochloride];
HALI: Hyperoxia induced acute lung injury; HMGB1: High mobility group box
protein 1; Hyperoxia: Greater than 99% oxygen; LPS: Lipopolysaccharide;
MCP-1: Monocyte chemoattractant protein-1; PA: Pseudomonas aeruginosa;
PMN: Polymorphonuclear cells; RA: Room air (21% Oxygen); RAGE: Receptor
for advanced glycation end-product; TNF: Tumor necrosis factor
Consent for publications
All authors read and approved the manuscript.
Authors’ contributions
RS, LLM, AG, ML, and SVF designed and performed experiments. RS, AG, ML,
and LLM analyzed data. SVF provided technical expertise in flow cytometry.
RS, AG, SVF, ML, MW, ATM, VAP, JCP, CRA, KJT, and LLM conceived the
project and wrote the paper. All authors read and approved the final
manuscript.
Funding
This study was funded by Grants from The National Heart and Blood Institute
(HL093708, to LLM) and intramural grants from St. John’s University (to LLM).
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was reviewed and approved by the IACUC at St. John’s University.
Competing interests
The authors have no competing interests to declare.
Received: 4 November 2019 Accepted: 29 April 2020
References
Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. Cutting edge: HMG-1 as a
mediator of acute lung inflammation. J Immunol. 2000;165(6):2950: 248–51.
Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation
and infection. Annu Rev Immunol. 2011;29:139–62.
Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H,
et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory
cytokine synthesis in human monocytes. J Exp Med. 2000;192(4):565–70.
Barnett N, Ware LB. Biomarkers in acute lung injury – marking forward Progress.
Crit Care Clin. 2011 Jul;27(3):661–83.
Belperio JA, Keane MP, Burdick MD, Londhe V, Xue YY, Li K, et al. Critical role for
CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced
lung injury. J Clin Invest. 2002;110(11):1703–16.
Bhandari V, Elias JA. Cytokines in tolerance to hyperoxia-induced injury in the
developing and adult lung. Free Radic Biol Med. 2006;41(1):4–18.
Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells
hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.
EMBO J. 2003;22(20):5551–60.
Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus
nerve stimulation attenuates the systemic inflammatory response to
endotoxin. Nature. 2000;405(6785):458–62.
Brewer SC, Wunderink RG, Jones CB, Leeper KV. Ventilator-associated pneumonia
due to Pseudomonas aeruginosa. Chest. 1996;109(4):1019.
Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al.
Recommendations for myeloid-derived suppressor cell nomenclature and
characterization standards. Nat Commun. 2016;7(1):1–10.
Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal
proteins. Trends Biochem Sci. 2001;26(3):152–3.
Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, et al. The lack of
chromosomal protein Hmg1 does not disrupt cell growth but causes lethal
hypoglycaemia in newborn mice. Nat Genet. 1999;22(3):276–80.
Carvalho CR. de Paula pinto Schettino G, Maranhao B, Bethlem EP. Hyperoxia and
lung disease. Curr Opin Pulm Med. 1998;4(5):300–4.
Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med.
2002;165(7):867.
Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, et al. Incidence of
and risk factors for ventilator-associated pneumonia in critically ill patients.
Ann Intern Med. 1998;129(6):433–40.
Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Annu Rev Physiol.
1986;48:721–31.
Sitapara et al. Molecular Medicine           (2020) 26:63 Page 10 of 12
Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER. Cell number and cell
characteristics of the Normal human lung 1–3. Am Rev Respir Dis. 1982;
126(2):332–7.
de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a
pharmacological target for inflammation. Br J Pharmacol. 2007;151(7):915.
Doerschuk CM. Leukocyte trafficking in alveoli and airway passages. Respir Res.
2000;1(3):136–40.
Entezari M, Javdan M, Antoine DJ, Morrow DMP, Sitapara RA, Patel V, et al.
Inhibition of extracellular HMGB1 attenuates Hyperoxia-induced inflammatory
acute lung injury. Redox Biol. 2014; 2: 314-322.
Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J, et al. Inhibition of
high-mobility group box 1 protein (HMGB1) enhances bacterial clearance
and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis.
Mol Med. 2012;18(1):477.
Garg BK, Loring RH. GTS-21 has cell-specific anti-inflammatory effects
independent of α7 nicotinic acetylcholine receptors. PLoS One. 2019;14(4):
e0214942.
Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19):
An updated overview for emergency clinicians. Emerg Med Pract. 2020;
22(5):1–28.
Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol
Med (Cambridge, Mass). 2011;17(3–4):293–307.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of
Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18): 1708-1720.
Han CH, Guan ZB, Zhang PX, Fang HL, Li L, Zhang HM, et al. Oxidative stress
induced necroptosis activation is involved in the pathogenesis of hyperoxic
acute lung injury. Biochem Biophys Res Commun. 2018;495(3):2178–83.
Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism
to translation. J Immunol. 2015;194(3):855–60.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;
395(10223):497–506.
Jiang Z, Zhou Q, Gu C, Li D, Zhu L. Depletion of circulating monocytes
suppresses IL-17 and HMGB1 expression in mice with LPS-induced acute
lung injury. Am J Physiol Lung Cell Mol Physiol. 2017;312(2):L231–42.
Kallet RH, Matthay MA. Hyperoxic acute lung injury. Respir Care. 2013;58(1):123–41.
Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and
disease. Mol Asp Med. 2014;40:1–116.
Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, et al. Safety,
pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21
in healthy. Male Volunteers Neuropsychopharmacology. 2003;28(3):542–51.
Kolliputi N, Shaik RS, Waxman AB. The inflammasome mediates hyperoxia-
induced alveolar cell permeability. J Immunol (Baltimore, Md: 1950). 2010;
184(10):5819–26.
Kox M, Pompe JC, Peters E, Vaneker M, van der Laak JW, van der Hoeven JG,
et al. alpha7 nicotinic acetylcholine receptor agonist GTS-21 attenuates
ventilator-induced tumour necrosis factor-alpha production and lung injury.
Br J Anaesth. 2011;107(4):559–66.
Kratofil RM, Kubes P, Deniset JF. Monocyte conversion during inflammation and
injury. Arterioscler Thromb Vasc Biol. 2017;37(1):35–42.
Lim JP, Leung BP, Ding YY, Tay L, Ismail NH, Yeo A, et al. Monocyte
chemoattractant protein-1: a proinflammatory cytokine elevated in
sarcopenic obesity. Clin Interv Aging. 2015;10:605–9.
Liu G, Wang J, Park Y-J, Tsuruta Y, Lorne EF, Zhao X, et al. High mobility group
protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to
phosphatidylserine. J Immunol. 2008;181(6):4240–6.
Lutz W, Stetkiewicz J. High mobility group box 1 protein as a late-acting
mediator of acute lung inflammation. Int J Occup Med Environ Health. 2004;
17(2):245–54.
Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, et al. The
genome of self-complementary adeno-associated viral vectors increases toll-
like receptor 9-dependent innate immune responses in the liver. Blood. 2011;
117(24):6459–68.
Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J
Clin Invest. 2012;122(8):2731–40.
Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress
syndrome: four decades of inquiry into pathogenesis and rational
management. Am J Respir Cell Mol Biol. 2005;33(4):319–27.
Mavropoulos SA, Khan NS, Levy ACJ, Faliks BT, Sison CP, Pavlov VA, et al. Nicotinic
acetylcholine receptor-mediated protection of the rat heart exposed to
ischemia reperfusion. Mol Med. 2017;23(1):120–33.
Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GRS, Perlman H. Flow
cytometric analysis of macrophages and dendritic cell subsets in the mouse
lung. Am J Respir Cell Mol Biol. 2013;49(4):503–10.
Mokra D, Kosutova P. Biomarkers in acute lung injury. Respir Physiol Neurobiol.
2015 Apr;209:52–8.
Morrow DMP, Entezari-Zaher T, Romashko J III, Azghani AO, Javdan M, Ulloa L,
et al. Antioxidants preserve macrophage phagocytosis of Pseudomonas
aeruginosa during hyperoxia. Free Radic Biol Med. 2007;42(9):1338–49.
Ogawa EN, Ishizaka A, Tasaka S, Koh H, Ueno H, Amaya F, et al. Contribution of
high-mobility group box-1 to the development of ventilator-induced lung
injury. Am J Respir Crit Care Med. 2006;174(4):400–7.
Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking.
Am J Phys Regul Integr Comp Phys. 2002;283(1):R7–28.
Patel VS, Sitapara RA, Gore A, Phan B, Sharma L, Sampat V, et al. High mobility
group box–1 mediates Hyperoxia-induced impairment of Pseudomonas
aeruginosa clearance and inflammatory lung injury in mice. Am J Respir Cell
Mol Biol. 2013;48(3):280–7.
Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, et al.
Selective [alpha] 7-nicotinic acetylcholine receptor agonist GTS-21
improves survival in murine endotoxemia and severe sepsis*. Crit Care
Med. 2007;35(4):1139.
Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung
injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med.
1997;155(4):1187–205.
Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M, Yang L, Valdés-Ferrer SI, Patel
NB, et al. The selective α7 agonist GTS-21 attenuates cytokine production in
human whole blood and human monocytes activated by ligands for TLR2,
TLR3, TLR4, TLR9, and RAGE. Mol Med. 2009;15(7–8):195.
Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, et al.
Cholinergic stimulation blocks endothelial cell activation and leukocyte
recruitment during inflammation. J Exp Med. 2005;201(7):1113–23.
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic
cells triggers inflammation. Nature. 2002;418(6894):191–5.
Silversides JA, Ferguson ND. Clinical review: acute respiratory distress syndrome -
clinical ventilator management and adjunct therapy. Crit Care. 2013;17(2):225.
Sitapara RA, Antoine DJ, Sharma L, Patel VS, Ashby CR Jr, Gorasiya S, et al. The
alpha7 nicotinic acetylcholine receptor agonist GTS-21 improves bacterial
clearance in mice by restoring hyperoxia-compromised macrophage
function. Mol Med (Cambridge, Mass). 2014;20(1):238–47.
Slutsky AS. Lung injury caused by mechanical ventilation. Chest. 1999;116(1
Suppl):9S–15S.
Snider GL, Rinaldo JE. Oxygen therapy, oxygen therapy in medical patients
hospitalized outside of the intensive care unit. Am Rev Respir Dis. 1980;122(5
Pt 2):29–36.
Steer JH, Mann TS, Lo SZY, Inglis JJ, Yap HS, Henry PJ, et al. Early induction of
uncoupling protein-2 in pulmonary macrophages in hyperoxia-associated
lung injury. Inhal Toxicol. 2013;25(9):544–52.
Su X, Lee JW, Matthay ZA, Mednick G, Uchida T, Fang X, et al. Activation of the α7
nAChR reduces acid-induced acute lung injury in mice and rats. Am J Respir
Cell Mol Biol. 2007;37(2):186–92.
Su X, Matthay MA, Malik AB. Requisite role of the cholinergic alpha7 nicotinic
acetylcholine receptor pathway in suppressing Gram-negative sepsis-induced
acute lung inflammatory injury. J Immunol (Baltimore, Md: 1950). 2010;184(1):
401–10..
Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P,
et al. Identification of splenic reservoir monocytes and their deployment to
inflammatory sites. Science. 2009;325(5940):612–6.
Szarka RJ, Wang N, Gordon L, Nation PN, Smith RH. A murine model of
pulmonary damage induced by lipopolysaccharide via intranasal instillation. J
Immunol Methods. 1997;202(1):49–57.
Taniguchi N, Kawahara KI, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al.
High mobility group box chromosomal protein 1 plays a role in the
pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis &
Rheumatism. 2003;48(4):971–81.
Tarnawski L, Reardon C, Caravaca AS, Rosas-Ballina M, Tusche MW, Drake AR,
et al. Adenylyl Cyclase 6 mediates inhibition of TNF in the inflammatory
reflex. Front Immunol. 2018;9:2648.
Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, et al.
Contributions of high mobility group box protein in experimental and
clinical acute lung injury. Am J Respir Critical Care Med. 2004:200402–
188OCv1.
Sitapara et al. Molecular Medicine           (2020) 26:63 Page 11 of 12
Valdés-Ferrer SI, Rosas-Ballina M, Olofsson PS, Lu B, Dancho ME, Ochani M, et al.
Expression of concern: HMGB1 mediates splenomegaly and expansion of
splenic CD11b+ Ly-6Chigh inflammatory monocytes in murine sepsis
survivors. J Intern Med. 2013;274(4):381–90.
van Zoelen MA, Ishizaka A, Wolthuls EK, Choi G, van der Poll T, Schultz MJ.
Pulmonary levels of high-mobility group box 1 during mechanical
ventilation and ventilator-associated pneumonia. Shock (Augusta, Ga).
2008;29(4):441–5.
Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1
as a late mediator of endotoxin lethality in mice. Science (New York, NY).
1999;285(5425):248–51.
Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists
inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med.
2004;10(11):1216–21.
Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic
acetylcholine receptor alpha7 subunit is an essential regulator of
inflammation. Nature. 2003;421(6921):384–8.
Wang M, Gauthier A, Daley L, Dial K, Wu J, Woo J, et al. Nuclear damage
associated molecular pattern (DAMP) molecule HMGB1 in the pathogenesis
of lung diseases. Antioxid Redox Signal. 2019;31(13): 954-993.
Windhorst C, Harth R, Wagoner C. Patients Requiring Tracheostomy and
Mechanical Ventilation. The ASHA Leader. 2009. https://doi.org/10.1044/
leader.FTR1.14012009.10 ss.
Xie K, Yu Y, Huang Y, Zheng L, Li J, Chen H, et al. Molecular hydrogen ameliorates
lipopolysaccharide-induced acute lung injury in mice through reducing
inflammation and apoptosis. Shock (Augusta, Ga). 2012;37(5):548–55.
Yang H, Liu H, Zeng Q, Imperato GH, Addorisio ME, Li J, et al. Inhibition of
HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-
HMGB1 antibodies, and cholinergic agonists suppresses inflammation. Mol
Med. 2019;25(1):–13.
Yang H, Wang H, Tracey KJ. HMG-1 rediscovered as a cytokine. Shock (Augusta,
Ga). 2001;15(4):247–53.
Yu Y-RA, O’Koren EG, Hotten DF, Kan MJ, Kopin D, Nelson ER, et al. A Protocol for
the Comprehensive Flow Cytometric Analysis of Immune Cells in Normal
and Inflamed Murine Non-Lymphoid Tissues. PLoS One. 2016;11(3):
e0150606.
Zhang L, Wang Y, Wu G, Xiong W, Gu W, Wang C-Y. Macrophages: friend or foe
in idiopathic pulmonary fibrosis? Respir Res. 2018;19(1): 170.
Zhang X, Shan P, Sasidhar M, Chupp GL, Flavell RA, Choi AMK, et al. Reactive
oxygen species and extracellular signal-regulated kinase 1/2 mitogen-
activated protein kinase mediate hyperoxia-induced cell death in lung
epithelium. Am J Respir Cell Mol Biol. 2003;28(3):305–15.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sitapara et al. Molecular Medicine           (2020) 26:63 Page 12 of 12
